In 2018, Domain Therapeutics and Boehringer Ingelheim entered into a multi-target collaboration and licensing agreement to address orphan GPCR for neuropsychiatric disorders and potential other indications (see press release).

Program description

Multi-target collaboration for CNS

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

Initiated in 2018, the multi-target drug discovery collaboration focuses on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area. The collaboration combines our expertise in the discovery of orphan GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications.

The achievement of two discovery milestones was announced in September 2019.

Other Programs

undisclosed targets


Anti-CCR8 monoclonal antibody for immuno-oncology